Human Growth Hormone

  • Michael J. Thomas
  • John A. Thomas


Human growth hormone (hGH) was discovered over three decades ago, and evidence of its therapeutic effectiveness was quickly recognized. Until recently, however, the therapeutic use of hGH was limited due to its scarcity and relatively high cost. Prior to recombinant-DNA-dervived (rDNA) hGH, the only source was from the pituitary glands of cadavers. In the human pituitary gland, approximately 10% of the dry weight of pituitary tissue is growth hormone.


Growth Hormone Short Stature Growth Hormone Deficiency Growth Hormone Secretion Human Growth Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Raiti S, Tolman RA (eds): Human Growth Hormone. New York, Plenum Medical Book Co., 1986.Google Scholar
  2. 2.
    Thomer MO, Vance ML, Evans WS, et al: Physiological and clinical studies of GRF and GH. Recent Prog Horm Res 42: 589–640, 1986.Google Scholar
  3. 3.
    Li CH, Chung C, Hans-Werner L, Stein S: The primary structure of monkey pituitary growth hormone. Arch Biochem Biophys 245: 287–291, 1986.PubMedCrossRefGoogle Scholar
  4. 4.
    Li CH, Bewley TA, Chung D, Oosthuizen MMJ: Elephant growth hormone. Int J Peptide Prot Res 29: 62–67, 1987.CrossRefGoogle Scholar
  5. 5.
    Thomas JA, Keenan EJ: Principles of Endocrine Pharmacology. New York, Plenum Publishing Co., 1986.Google Scholar
  6. 6.
    Isaksson OGP, Eden S, Jansson J-O: Mode of action of pituitary growth hormone on target cells. Annu Rev Physiol 47: 483–499, 1985.PubMedCrossRefGoogle Scholar
  7. 7.
    Hughes JP, Friesen HG: The nature and regulation of the receptors for pituitary growth hormone. Annu Rev Physiol 47: 469–482, 1985.PubMedCrossRefGoogle Scholar
  8. 8.
    Robbins SL, Cotran RS, Kumar V: Pathologic Basis of Disease, ed 3. Philadelphia, W.B. Saunders Co., 1984, pp 1192–1200.Google Scholar
  9. 9.
    Murad F, Haynes RC Jr: Adenohypophyseal hormones and related substances, in Gilman AG, Goodman LS, Rall TW, Murad F (eds): The Pharmacological Basis of Therapeutics, ed 7. New York, Macmillan Publishing Co., 1985, pp 1362–1388.Google Scholar
  10. 10.
    Daughaday WH: The anterior pituitary, in Wilson JD, Foster DW (eds): Williams Textbook of Endocrinology, ed 7. Philadelphia, W. B. Saunders Co., 1985, pp 568–613.Google Scholar
  11. 11.
    Underwood LE, Van Wyk JJ: Normal and aberrant growth, in Wilson JD, Foster DW (eds): Williams Textbook of Endocrinology, ed 7. Philadelphia, W.B. Saunders Co., 1985, pp 155–205.Google Scholar
  12. 12.
    Froesch ER, Schmid C, Schwander J, Zapf J: Actions of insulin-like growth factors. Annu Rev Physiol 47: 443–467, 1985.PubMedCrossRefGoogle Scholar
  13. 13.
    Weyer B, Sonne O: Receptor-mediated degradation of human growth hormone in rat adipocytes and cultured human lymphocytes (IM-9). Mol Cell Endocrinol 41: 85–92, 1985.PubMedCrossRefGoogle Scholar
  14. 14.
    Yamada K, Lipson K, Marino MW, Donner DB: Effect of growth hormone on protein phosphorylation in isolated rat hepatocytes. Biochemistry 26: 715–721, 1987.PubMedCrossRefGoogle Scholar
  15. 15.
    Hunter T, Alexander CB, Cooper JA: Protein phosphorylation and growth control, in Growth Factors in Biology and Medicine (Ciba Foundation Symposium 116 ). London, Pitman, 1985, pp 188–204.Google Scholar
  16. 16.
    Gertler A, Friesen HG: Human growth hormone-stimulated mitogenesis of Nb2 node lymphoma cells is not mediated by an immediate acceleration of phosphoinositide metabolism. Mol Cell Endocrinol 48: 221–228, 1986.PubMedCrossRefGoogle Scholar
  17. 17.
    Mittra I: Somatomedins and proteolytic bioactiviation of prolactin and growth hormone. Cell 38: 347348, 1984.Google Scholar
  18. 18.
    Clemmons DR, Underwood LE: Somatomedin-C/insulin-like growth factor I in acromegaly. Clin Endocrinol Metab 15 (3): 629–653, 1986.PubMedCrossRefGoogle Scholar
  19. 19.
    Christy NP: The anterior pituitary: assessment of anterior pituitary function, in Wyngaarden JB, Smith LH Jr (eds): Cecil’s Textbook of Medicine, ed 16. Philadelphia, W. B. Saunders Co., 1982, pp 1172–1174.Google Scholar
  20. 20.
    Zapf J, Schoenle E, Froesch ER: In vivo effects of the insulin-like growth factors (IGFs) in the hypophysectomized rat: comparison with human growth hormone and the possible role of the specific IGF carrier proteins, in Growth Factors in Biology and Medicine (CIBA Foundation Symposium 116 ). London, Pitman, 1985, pp 169–187.Google Scholar
  21. 21.
    Mathews LS, Norstedt G, Palmiter RS: Regulation of insulin-like growth factor-I gene expression by growth hormone. Proc Natl Acad Sci USA 83 (24): 9343–9347, 1987.CrossRefGoogle Scholar
  22. 22.
    Grant MB, Schmetz I, Russell B, et al: Changes in insulin-like growth factors I and II and their binding protein after a single intramuscular injection of growth hormone. J Clin Endocrinol Metab 63(4):981–984, 1986.PubMedCrossRefGoogle Scholar
  23. 23.
    Zezulak KM, Green H: The generation of insulin-like growth factor-I-sensitive cells by growth hormone action. Science 233: 551–553, 1986.PubMedCrossRefGoogle Scholar
  24. 24.
    Skottner A, Fryklund L, Hansson HA: Experimental research on IGF-1. Acta Paediatr Scand 325 (suppl): 107–114, 1986.CrossRefGoogle Scholar
  25. 25.
    Brook CGD, Hindmarsh PC, Smith PJ, Stanhope R: Clinical features and investigation of growth hormone deficiency. Clin Endocrinol Metab 15 (3): 479–493, 1986.PubMedCrossRefGoogle Scholar
  26. 26.
    Schaff-Blass E, Burstein S, Rosenfield RL: Advances in diagnosis and treatment of short stature, with special reference to the role of growth hormone. J Pediatr 104: 801–813, 1984.PubMedCrossRefGoogle Scholar
  27. 27.
    Scheithauer BW, Kovacs K, Randall RV, et al: Pathology of excessive production of growth hormone. Clin Endocrinol Metab 15 (3): 655–681, 1986.PubMedCrossRefGoogle Scholar
  28. 28.
    Bercu BB, Diamond FB: Growth hormone neurosecretory dysfunction. Clin Endocrinol Metab 15 (3): 537–590, 1986.PubMedCrossRefGoogle Scholar
  29. 29.
    Grossman A, Savage MO, Besser GM: Growth hormone releasing hormone. Clin Endocrinol Metab 15 (3): 607–627, 1986.PubMedCrossRefGoogle Scholar
  30. 30.
    Wass JAH, Laws ER Jr, Randall RV, Sheline GE: The treatment of acromegaly. Clin Endocrinol Metab 15 (3): 683–707, 1986.PubMedCrossRefGoogle Scholar
  31. 31.
    Oppizzi G, Petroncini MM, Dallabonzana D, et al: Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation. J ClinEndocrinol Metab 63(6):13481353, 1986.Google Scholar
  32. 32.
    Bercu BB, Shulman D, Root AW, Spiliotis BE: Growth hormone (GH) provocative testing frequently does not reflect endogenous GH secretion. J Clin Endocrinol Metab 63 (3): 709–716, 1986.PubMedCrossRefGoogle Scholar
  33. 33.
    Albertsson-Wikland K: Growth hormone treatment in short children. Acta Paediatr Scand 325 (suppl): 6470, 1986.Google Scholar
  34. 34.
    Takano K, Hizuka N, Shizume K: Treatment of Turner’s syndrome with methionyl human growth hormone for six months. Acta Endocrinol 112: 130–137, 1986.PubMedGoogle Scholar
  35. 35.
    Schwartz J, Foster CM: Pituitary and recombinant deoxyribonucleic derived human growth hormones alter glucose metabolism in 3T3 adipocytes. J Clin Endocrinol Metab 62 (4): 791–794, 1986.PubMedCrossRefGoogle Scholar
  36. 36.
    Bierich JR: Treatment of pituitary dwarfism with biosynthetic growth hormone. Acta Paediatr Scand 325 (suppl): 13–18, 1986.CrossRefGoogle Scholar
  37. 37.
    Girard F, Gourmelen M: Clinical experience with somatonorm. Acta Paediatr Scand 325 (suppl): 29–32, 1986.CrossRefGoogle Scholar
  38. 38.
    Milner RDG: Clinical experience with somatren: UK preliminary report. Acta Paediatr Scand 325 (suppl): 25–28, 1986.CrossRefGoogle Scholar
  39. 39.
    Takano K, Shizume K: Clinical experience with somatrem in Japan. Acta Paediatr Scand 325 (suppl): 1924, 1986.Google Scholar
  40. 40.
    Vicens-Calvet E, Potau N, Carracosa A, et al: Clinical experience with somatrem in growth hormone deficiency. Acta Paediatr Scand 325 (suppl): 33–40, 1986.CrossRefGoogle Scholar
  41. 41.
    Westphal O: Experiences of somatonorm in Sweden. Acta Paediatr Scand 325 (suppl): 41–44, 1986.CrossRefGoogle Scholar
  42. 42.
    Brown P, Gajdusek DC, Gibbs CJ, Asher DM: Potential epidemic of Creutzfeldt—Jakob disease from human growth hormone therapy. N Engl J Med 313: 728–731, 1985.PubMedCrossRefGoogle Scholar
  43. 43.
    Underwood LE: Report on the conference on uses and possible abuses of biosynthetic human growth hormone. N Engl J Med 311: 606–608, 1984.PubMedCrossRefGoogle Scholar
  44. 44.
    Andersson R: Immunological aspects of growth hormone. Acta Paediatr Scand 325 (suppl): 48–54, 1986.CrossRefGoogle Scholar
  45. 45.
    Kaplan SL: Current status of the treatment of growth hormone deficiencies. 68th Annual Meeting Endocrine Society Proceedings, June, 1986.Google Scholar
  46. 46.
    Ranke MB, Bierich JR: Treatment of growth hormone deficiency. Clin Endocrinol Metab 15(3):495510, 1986Google Scholar
  47. 47.
    Fryklund LM, Bierich JR, Ranke MB: Recombinant human growth hormone. Clin Endocrinol Metab 15 (3): 511–535, 1986PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1988

Authors and Affiliations

  • Michael J. Thomas
    • 1
  • John A. Thomas
    • 2
  1. 1.Department of Pharmacology and ToxicologyWest Virginia University School of MedicineMorgantownUSA
  2. 2.Department of PharmacologyUniversity of Texas Health Science CenterSan AntonioUSA

Personalised recommendations